Menu

MD Anderson Cancer Center Head Resigns

Ronald DePinho tells institute employees it is “time for a change in leadership.”

Mar 9, 2017
Tracy Vence

The University of Texas MD Anderson Cancer Center president is stepping down. Ronald DePinho, who has led the institution for nearly six years and was involved in managerial and financial controversies, wrote in a letter to his staff that it is “time for a change in leadership.”

As the Houston Chronicle noted, “DePinho’s [leadership] at MD Anderson was marked by change, criticism, and challenges.” In March 2013, for example, around one-third of institute employees who responded to a survey indicated dissatisfaction with his management. That May, The Cancer Letter reported that the institute spent around $1.5 million in building renovations for DePinho’s wife, Lydia Chin, chair of MD Anderson’s genomic medicine department. The institute disputed the report at the time.

In 2016, the institute reported significant operating losses. MD Anderson “was expecting to lose as much as $450 million in 2017,” STAT News reported, “though it brings in about $4 billion in annual revenue.”

“In an era of significant and rapid financial change, we are recovering well from short-term challenges and, longer term, have diversified our revenue streams through philanthropy, strategic ventures and innovation,” DePinho wrote in his letter, adding: “I could have done a better job administratively, a better job listening, a better job communicating. Forgive me for my short comings [sic].”

THUMBNAIL IMAGE: WIKIMEDIA, UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER

July 2019

On Target

Researchers strive to make individualized medicine a reality

Marketplace

Sponsored Product Updates

DNASTAR® announced the release of Lasergene 16 Software
DNASTAR® announced the release of Lasergene 16 Software
DNASTAR® announced the release of Lasergene 16 today, which includes a broad range of improvements in for analysis of DNA, RNA and protein sequence data, as well as new advancements for predicting and analyzing protein structures. 
Arbor Biosciences Partners with Curio Genomics for Analysis of IWGSC Wheat Exome
Arbor Biosciences Partners with Curio Genomics for Analysis of IWGSC Wheat Exome
Arbor Biosciences, a division of Chiral Technologies, Inc and worldwide leader in next generation sequencing (NGS) target enrichment, announces a partnership with Curio Genomics for bioinformatics analysis of the wheat genome.
IDT and Washington University join forces to increase access to the latest NGS technologies
IDT and Washington University join forces to increase access to the latest NGS technologies
As part of its commitment to advocate for the genomics age, Integrated DNA Technologies (IDT) aims to lower the barriers to access the latest NGS technologies.
Bio-Rad Launches Bio-Plex Pro Human Immunotherapy Panel 20-plex Multiplex Assay, a targeted tool for researching signaling networks in Immunotherapy Research
Bio-Rad Launches Bio-Plex Pro Human Immunotherapy Panel 20-plex Multiplex Assay, a targeted tool for researching signaling networks in Immunotherapy Research
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) July 15, 2019 announced the launch of its Bio-Plex Pro Human Immunotherapy Panel 20-plex, a multiplex immunoassay that offers a targeted approach for Immunotherapy Research.